Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3K δ inhibitor under development for the treatment of COPD

Conclusions In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients. Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor. Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research